Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company funded the PH Diagnostics acquisition (₹147.50 crores) entirely through existing cash reserves. Post-acquisition and dividend payment, the cash reserve stands at ₹158 crores. The strong cash position and healthy balance sheet are highlighted as supporting future expansion. No indications were given about raising additional capital via equity or debt at this time.

Any current/future capex/capital investment/strategic investment?

The company continues to expand into new geographies following a well-thought-out expansion strategy. Recent significant acquisition: PH Diagnostics in Pune for Rs.147.5 crores, fully funded from existing cash reserves. The company is close to reaching 150 centers across 23 cities and 5 states. New hub centers recently launched at Mahbubnagar and Gulbarga as part of Tier-2 city and adjacent geography expansion. Additional two spokes added in Hyderabad network in the recent year. Plans to open 12 to 15 centers annually remain intact, although some may spill over to the next financial

Future growth expectations in sales/revenue/volumes?

The company expects a 14% to 15% growth primarily driven by volume growth (around 15% test volume growth). Non-COVID revenue grew 17% YoY, with 18% volume growth including PH acquisition impact. Volume growth is driven by both existing and new centers across geographies including Hyderabad, Pune, Kolkata, and Tier-2/ Tier-3 cities. Hyderabad remains a key growth market expected to sustain high double-digit growth for the next 2-3 years. The contribution from Hyderabad, currently ~80%, is expected to reduce to approximately 70-75% as other markets like Andhra, Pune, and Eastern India gr

Future growth expectations in earnings/operating earnings/profits/EPS?

Vijaya Diagnostic Centre expects overall revenue growth of around 15% driven mainly by volume growth across geographies including Hyderabad, Pune, Tier-2 and Tier-3 cities, and East India. PH Diagnostics acquisition in Pune is expected to contribute incremental revenue with growth potential beyond FY24. EBITDA margins are expected to remain healthy around 39-40%, supported by operational efficiencies and integrated business model. Price increases are minimal (~1-1.5%) and earnings growth is volume-led. Hyderabad, the largest market (~80% revenue currently), will sustain double-digit growth for

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention current or expected orderbook or pending orders. Focus is on expansion plans including hubs and spokes, especially in Hyderabad and Pune. 15 centers are planned to open annually, though some may spill over to the next financial year due to delays. PH Diagnostics acquisition in Pune is fully integrated and expected to contribute to growth. The company is expanding steadily in Tier-2 and adjacent geographies with hubs already opened in Mahbubnagar and Gulbarga. Management emphasizes a careful, strategic expansion rather than rapid scaling. No specific f

Vijaya Diagnost.Q3 FY24Healthcare Services

Vijaya Diagnost. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,428P/E: 83.2Market Cap: ₹15.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects a 14% to 15% growth primarily driven by volume growth (around 15% test volume growth).
Non-COVID revenue grew 17% YoY, with 18% volume growth including PH acquisition impact.
Volume growth is driven by both existing and new centers across geographies including Hyderabad, Pune, Kolkata, and Tier-2/ Tier-3 cities.
Hyderabad remains a key growth market expected to sustain high double-digit growth for the next 2-3 years.
The contribution from Hyderabad, currently ~80%, is expected to reduce to approximately 70-75% as other markets like Andhra, Pune, and Eastern India grow.
PH Pune acquisition (~Rs.42 crores revenue in FY23) is expected to grow further and contribute to revenue scaling.
The company plans to continue adding 12-15 centers annually, with expansion focused on existing and adjacent geographies.
Price hikes are limited (~1-1.5% annually); growth is volume-driven rather than price-driven.

Margin guidance

Category 3

Vijaya Diagnostic Centre expects overall revenue growth of around 15% driven mainly by volume growth across geographies including Hyderabad, Pune, Tier-2 and Tier-3 cities, and East India.
PH Diagnostics acquisition in Pune is expected to contribute incremental revenue with growth potential beyond FY24.
EBITDA margins are expected to remain healthy around 39-40%, supported by operational efficiencies and integrated business model.
Price increases are minimal (~1-1.5%) and earnings growth is volume-led.
Hyderabad, the largest market (~80% revenue currently), will sustain double-digit growth for next 2-3 years with focus also shifting to Pune and East India.
Expansion strategy includes opening 12-15 new centers annually with hubs in Pune and Kolkata to ramp up, supporting long-term growth.
Solid cash reserves (Rs.158 crores post-acquisition) support organic and inorganic expansion.
Early break-even hubs (e.g., Kolkata) and new markets (Gulbarga) show promising ramp-up for profit contribution.
EPS growth expected to follow steady revenue and margin expansion over next 3-5 years.

See what Vijaya Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the transcript.
The company funded the PH Diagnostics acquisition (₹147.50 crores) entirely through existing cash reserves.
Post-acquisition and dividend payment, the cash reserve stands at ₹158 crores.
The strong cash position and healthy balance sheet are highlighted as supporting future expansion.
No indications were given about raising additional capital via equity or debt at this time.

Order book

The transcript does not explicitly mention current or expected orderbook or pending orders.
Focus is on expansion plans including hubs and spokes, especially in Hyderabad and Pune.
15 centers are planned to open annually, though some may spill over to the next financial year due to delays.
PH Diagnostics acquisition in Pune is fully integrated and expected to contribute to growth.
The company is expanding steadily in Tier-2 and adjacent geographies with hubs already opened in Mahbubnagar and Gulbarga.
Management emphasizes a careful, strategic expansion rather than rapid scaling.
No specific figures about orderbook or pending orders are disclosed in this call.

See what Vijaya Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company continues to expand into new geographies following a well-thought-out expansion strategy.
Recent significant acquisition: PH Diagnostics in Pune for Rs.147.5 crores, fully funded from existing cash reserves.
The company is close to reaching 150 centers across 23 cities and 5 states.
New hub centers recently launched at Mahbubnagar and Gulbarga as part of Tier-2 city and adjacent geography expansion.
Additional two spokes added in Hyderabad network in the recent year.
Plans to open 12 to 15 centers annually remain intact, although some may spill over to the next financial year due to delays.
Expect increased CAPEX in Pune region with 2-3 hubs expected after acquisition integration.
In Kolkata, gradual, organic growth with 1 hub opening every two quarters; East India expansion continues at a measured pace.
The company is focusing on integrating PH's operations fully in the next two quarters, including front-end and back-end processes.

Track Vijaya Diagnost. — get its next earnings analysis in your feed

How does Vijaya Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisVijaya Diagnost.

Rev 3Mar 3

See where Vijaya Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vijaya Diagnost. rank in Healthcare Services?

Compare Vijaya Diagnost. against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vijaya Diagnost. Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vijaya Diagnost. rank in Healthcare Services?

Continue your research

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season